FDA Approves First Gene Therapy for Adults With Hemophilia B
MONDAY, Nov. 28, 2022 -- The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.
Hemgenix, an adeno-associated virus vector-based gene therapy, is administered via...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Adenoviruses | Food and Drug Administration (FDA) | Gene Therapy | General Medicine | Genetics | Haemophilia | Hemophilia